Clinical Trials
45 trialsNCT05355701 2026-06-05
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05538130 2026-06-05
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT07302347 2026-06-05
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT04458259 2026-06-04
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT04566393 2026-06-04
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT04895709 2026-06-04
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07627698 2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2 Recruiting
NCT01009177 2026-06-03
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Actelion
Phase 2 Completed
NCT05625399 2026-06-03
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03771859 2026-06-02
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
Bristol-Myers Squibb
Completed
NCT04083599 2026-06-02
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT06984328 2026-06-02
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT07227350 2026-06-02
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Philogen S.p.A.
Phase 2 Recruiting
NCT07584226 2026-06-02
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
Phase 1 Recruiting
NCT07619898 2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2 Not yet recruiting
NCT02332668 2026-06-01
MK-3475-051
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT02073123 2026-05-29
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Lumos Pharma
Phase 1/2 Completed
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT06171178 2026-05-29
A Study of ASP1012 in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1 Terminated
NCT06743126 2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT07492680 2026-05-29
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT04305054 2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT06131398 2026-05-28
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
Phase 1 Active not recruiting
NCT06153238 2026-05-28
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Sandoz
Phase 1 Active not recruiting
NCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05068102 2026-05-27
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06880549 2026-05-27
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT03941379 2026-05-22
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Aura Biosciences
Active not recruiting
NCT04541108 2026-05-22
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Active not recruiting
NCT05662202 2026-05-22
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT06953089 2026-05-22
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 2 Recruiting
NCT07070232 2026-05-22
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
Phase 1/2 Recruiting
NCT05537740 2026-05-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT06305247 2026-05-20
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Active not recruiting
NCT07600476 2026-05-20
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Kupando GmbH
Phase 1 Recruiting
NCT02943642 2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2 Withdrawn
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT05379985 2026-05-15
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06172478 2026-05-15
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 2 Recruiting
NCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT07160335 2026-05-15
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
Phase 1 Recruiting